They found that among the six BC cell lines tested, the VDR agonists more efficiently enhanced 5-fluorouracil anticancer activity in the luminal subtypes [54]; thus, showing similar results to those just described with calcitriol and paclitaxel. The gene discussed is VDR; the disease is breast cancer.